Quantcast
Last updated on April 20, 2014 at 8:04 EDT

Latest Tau protein Stories

2013-02-12 20:24:47

Neuron have discovered an abnormal protein that first forms as a result of genetic abnormalities and later builds up in the brains of many patients with either disease. "In identifying the novel protein that abnormally accumulates in the brains of affected patients, we have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases," says senior author Dr. Leonard Petrucelli, Chair of Neuroscience at Mayo Clinic in Florida....

2013-01-23 10:16:32

Deleting or reducing expression of a gene that carries the code for tau, a protein associated with Alzheimer's disease, can prevent seizures in a severe type of epilepsy linked to sudden death, said researchers at Baylor College of Medicine and the Mayo Clinic in Jacksonville, Fla., in a report in the current issue of the Journal of Neuroscience. A growing understanding of the link between epilepsy and some forms of inherited Alzheimer's disease led to the finding that could point the way...

2012-12-05 08:27:02

VANCOUVER, Dec. 5, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that the United States, New Zealand and Mexican patent authorities have each issued composition of matter patents for a new family of peptides that the Company believes has the potential to be developed to treat neurological and neurodegenerative diseases. This new platform is derived from a protein involved in the function of microtubules that are critical to the correct structure and...

2012-10-30 11:26:21

MONTE CARLO, Monaco, October 30, 2012 /PRNewswire/ -- The time for Tau is now as Phase 3 clinical trials get under way with a second-generation Tau Aggregation Inhibitor (TAI) aimed at halting the progression of Alzheimer's TauRx Therapeutics Ltd announced today the initiation of two global Phase 3 clinical trials in mild to moderate Alzheimer's disease. These landmark studies could provide the first definitive data on a...

2012-09-09 22:24:18

MANCHESTER, England, September 10, 2012 /PRNewswire/ -- Investigational drug study follows earlier study with promising results in mild to moderate Alzheimer's patients TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7...

2012-08-24 00:23:33

Researchers find that optimal length of mitochondria in neurons is essential to preventing onset of Alzheimer's and other tau-related diseases Goldilocks was on to something when she preferred everything "just right." Harvard Medical School researchers have found that when it comes to the length of mitochondria, the power-producing organelles, applying the fairy tale's mantra is crucial to the health of a cell. More specifically, abnormalities in mitochondrial length promote the...

2012-06-13 13:06:48

Researchers from Boston University School of Medicine (BUSM) have identified a novel group of proteins that accumulate in the brains of patients with Alzheimer's disease. These findings, which appear online in the Journal of Neuroscience, may open up novel approaches to diagnose and stage the progression likelihood of the disease in Alzheimer patients. Alzheimer's disease is presumed to be caused by the accumulation of β-amyloid, which then induces aggregation of a neuronal protein,...

2012-06-04 04:21:37

(Ivanhoe Newswire) - 5.4 million Americans suffer from Alzheimers and 3 million from Parkinson's disease. Doctors who treat patients with these among other neurodegenerative conditions believe that the diseases are spreading though their patients' brains. The stages of both Alzheimers and Parkinson's disease show these pathological effects. Until recently, only in prion disease had this spread been shown, resulting in proof that the agent of spread is the prion protein. More recently,...

2012-05-01 23:03:45

Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer´s disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function. New York, NY (PRWEB) May 01, 2012...

2012-04-24 10:01:08

Without p-tau protein present, impact of amyloid is 'not significantly different from zero' According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau. Without both, progressive clinical decline associated with AD in cognitively healthy older individuals is "not significantly different from...